Biofermin Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biofermin Pharmaceutical Company Limited with three other
companies in this sector in Japan:
Koei Chemical Company, Limited
sales of 18.14 billion Japanese Yen [US$161.84 million]
Wakamoto Pharmaceutical Co., Ltd.
(10.90 billion Japanese Yen [US$97.24 million]
of which 51%
was Medical Pharmaceutical Products), and
I'rom Group Co Ltd
(8.62 billion Japanese Yen [US$76.90 million]
of which 73%
was Smo Business).
Biofermin Pharmaceutical Company Limited reported sales of ¥10.88 billion (US$97.03 million)
March of 2018.
increase of 2.4%
versus 2017, when the company's sales were ¥10.62 billion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Biofermin Pharmaceutical Company Limited had sales
of ¥10.31 billion.
Sales of Biofermin Synthetic Drugs saw an increase
that was more than double the company's growth rate: sales were up
8.1% in 2018, from
¥776.50 million to ¥839.28 million.
Biofermin Pharmaceutical Company Limited also saw significant increases in sales in
New Biofermins (up 3.7% to ¥6.79 billion)
Biofermin Tablet (up 3.4% to ¥1.96 billion)
Not all segments of Biofermin Pharmaceutical Company Limited experienced an increase in sales in 2018:
sales of Other fell 16.9% to ¥583.17 million.